Home » Stocks » KMPH

KemPharm, Inc. (KMPH)

Stock Price: $8.89 USD -0.61 (-6.42%)
Updated May 10, 2021 4:00 PM EDT - Market closed
After-hours: $8.87 -0.02 (-0.23%) May 10, 5:41 PM
Market Cap 270.65M
Revenue (ttm) 13.29M
Net Income (ttm) -12.76M
Shares Out 3.98M
EPS (ttm) -3.21
PE Ratio n/a
Forward PE 30.12
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $8.89
Previous Close $9.50
Change ($) -0.61
Change (%) -6.42%
Day's Open 9.43
Day's Range 8.68 - 9.45
Day's Volume 798,226
52-Week Range 0.20 - 18.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

KP879, KemPharm's Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA

3 days ago - GlobeNewsWire

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET

4 days ago - GlobeNewsWire

Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX

2 weeks ago - GlobeNewsWire

KemPharm Inc (NASDAQ: KMPH) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to d...

1 month ago - Benzinga

Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales

1 month ago - GlobeNewsWire

KemPharm has a new ADHD drug, but after a recent short-squeeze KMPH stock is likely to fall without further financing. The post KemPharm Stock Is Too Good to Be True After Its Recent Run-up appeared fir...

1 month ago - InvestorPlace

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME). The post KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Sque...

Other stocks mentioned: TWTR
1 month ago - InvestorPlace

Corporate and Regulatory Highlights:

1 month ago - GlobeNewsWire

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

2 months ago - GlobeNewsWire

CELEBRATION, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced ...

2 months ago - GlobeNewsWire

KemPharma (KMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

2 months ago - Zacks Investment Research

What a day. We saw the morning start with a new iteration of the Reddit stocks rally, and the afternoon close with new fears about digital ad companies.

Other stocks mentioned: FVRR, SOS
2 months ago - InvestorPlace

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

2 months ago - Zacks Investment Research

Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesd...

Other stocks mentioned: SRNE
2 months ago - Benzinga

KemPharm's prodrug development platform got a huge boost from the FDA's new drug application nod for an ADHD treatment. The post KMPH Stock: The Big News That Has KemPharm Soaring Today appeared first o...

2 months ago - InvestorPlace

The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (AD...

2 months ago - Benzinga

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

2 months ago - GlobeNewsWire

Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Financial Restructuring and Nasdaq Re-Listing Process Completed

3 months ago - GlobeNewsWire

Combination of Oral and Poster Presentations Scheduled for January 15, 2021

3 months ago - GlobeNewsWire

CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced t...

3 months ago - GlobeNewsWire

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021

4 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...

4 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it...

4 months ago - GlobeNewsWire

CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced th...

5 months ago - GlobeNewsWire

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

5 months ago - GlobeNewsWire

IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline , Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH)

5 months ago - GlobeNewsWire

Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET

5 months ago - GlobeNewsWire

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET

6 months ago - GlobeNewsWire

Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020, 8:00 a.m. ET

6 months ago - GlobeNewsWire

CELEBRATION, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced th...

6 months ago - GlobeNewsWire

New agreement provides additional revenue potentially through Q1 2022

7 months ago - GlobeNewsWire

4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty

Other stocks mentioned: ALDX, NERV, SAVA
7 months ago - Zacks Investment Research

CELEBRATION, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietar...

7 months ago - GlobeNewsWire

Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment

8 months ago - GlobeNewsWire

Presentations to Highlight Corporate, Regulatory and Pipeline Advancements Presentations to Highlight Corporate, Regulatory and Pipeline Advancements

8 months ago - GlobeNewsWire

CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced ...

8 months ago - GlobeNewsWire

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesd...

9 months ago - GlobeNewsWire

New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037

9 months ago - GlobeNewsWire

CELEBRATION, Fla., June 18, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced ...

10 months ago - GlobeNewsWire

We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.

Other stocks mentioned: COCP, ECOR, INSE
10 months ago - Forbes

FDA Sets PDUFA Date of March 2, 2021

11 months ago - GlobeNewsWire

KemPharma (KMPH) delivered earnings and revenue surprises of -1100.00% and -63.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET

11 months ago - GlobeNewsWire

Corium, GPC’s portfolio company, to lead all commercialization activities for KP415

1 year ago - GlobeNewsWire

If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products

1 year ago - GlobeNewsWire

About KMPH

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CN... [Read more...]

Industry
Biotechnology
IPO Date
Apr 16, 2015
CEO
Travis Mickle
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
KMPH
Full Company Profile

Financial Performance

In 2020, KemPharm's revenue was $13.29 million, an increase of 3.50% compared to the previous year's $12.84 million. Losses were -$12.76 million, -47.97% less than in 2019.

Financial Statements